Alpine Immune Sciences Inc (ALPN)
64.60
0.00 (0.00%)
USD |
NASDAQ |
May 02, 11:41
Alpine Immune Sciences Revenue (Quarterly): 30.85M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 30.85M |
September 30, 2023 | 10.04M |
June 30, 2023 | 8.593M |
March 31, 2023 | 9.387M |
December 31, 2022 | 2.776M |
September 30, 2022 | 8.367M |
June 30, 2022 | 5.292M |
March 31, 2022 | 13.63M |
December 31, 2021 | 4.53M |
September 30, 2021 | 8.516M |
June 30, 2021 | 7.193M |
March 31, 2021 | 3.204M |
December 31, 2020 | 5.643M |
Date | Value |
---|---|
September 30, 2020 | 1.913M |
June 30, 2020 | 0.688M |
March 31, 2020 | 1.091M |
December 31, 2019 | 0.884M |
September 30, 2019 | 0.289M |
June 30, 2019 | 0.567M |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | 0.39M |
March 31, 2018 | 0.315M |
December 31, 2017 | 0.128M |
September 30, 2017 | 0.128M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.289M
Minimum
Sep 2019
30.85M
Maximum
Dec 2023
6.498M
Average
5.292M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 2.518B |
Eliem Therapeutics Inc | -- |
Regeneron Pharmaceuticals Inc | 3.434B |
Vera Therapeutics Inc | -- |
Eyenovia Inc | 0.0026M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 5.96M |
Total Expenses (Quarterly) | 29.31M |
EPS Diluted (Quarterly) | 0.15 |
Enterprise Value | 3.908B |
Profit Margin (Quarterly) | 19.32% |
Earnings Yield | -0.99% |
Normalized Earnings Yield | -0.9908 |